迈威生物9MW3811注射液临床试验获批

Core Viewpoint - Maiwei Biotech has received approval from the National Medical Products Administration for the clinical trial of its drug 9MW3811, aimed at treating pathological scars in a Phase II study [1] Group 1: Company Overview - 9MW3811 is a humanized monoclonal antibody targeting human IL-11, developed independently by Maiwei Biotech [1] - The drug is classified as a Class 1 therapeutic biological product [1] Group 2: Product Details - 9MW3811 works by binding with high affinity to IL-11, effectively inhibiting the abnormal activation of the IL-11/IL-11Rα signaling pathway [1] - The mechanism of action is aimed at intervening in the pathological progression of fibrotic diseases [1]